Elevating Cancer Treatment: Inceptor Bio Secures $21M to Power Next‑Generation CAR‑T Therapies

Inceptor Bio, a pioneering clinical-stage biotech company dedicated to reimagining cancer treatment, is thrilled to announce its recent funding round that raised $21,000,000. This crucial investment will catalyze our mission to develop next-generation cell therapies engineered to overcome the formidable challenges posed by aggressive cancers. At the core of our innovation is the proprietary OUTLAST™ platform, which reprograms T cells into persistent, stem-like cells capable of thriving within the hostile tumor microenvironment. Much like elite athletes who train at high altitudes to develop strength and endurance, our T cells undergo a rigorous conditioning process that equips them with robust capabilities, far surpassing those grown under conventional laboratory conditions. The funds will primarily be directed towards advancing our lead program, IB-T101, an autologous CD70 CAR-T therapy specifically designed to target clear cell Renal Cell Carcinoma (ccRCC). This groundbreaking therapy holds promise in addressing the complex biology of ccRCC by leveraging the enhanced persistence and resilience of our engineered T cells. With this strategic infusion of resources, our teams are poised to accelerate clinical development, spearhead critical research, and further refine our manufacturing processes to ensure that our treatments can reach patients as swiftly and safely as possible. Our commitment at Inceptor Bio is driven by an unwavering belief that by pushing the boundaries of cellular engineering, we can redefine the future of cancer therapy. As we embark on this exciting phase of growth fueled by investor confidence and financial support, we invite you to join us on our journey to transform cancer care and create hope for patients worldwide.